Immune checkpoint inhibitors and renal toxicity.

Bocchi, F; Häfliger, S; Schmid, S; Sidler, D (2024). Immune checkpoint inhibitors and renal toxicity. Heliyon, 10(11) Elsevier 10.1016/j.heliyon.2024.e31911

Preview

Text 1-s2.0-S2405844024079428-main.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (377kB) | Preview

Immune checkpoint inhibitors (ICIs) have transformed the management of a broad spectrum of cancers as metastatic melanoma, non-small lung cancer or renal cell carcinoma. These humanized monoclonal antibodies target immune-regulatory receptors expressed on T lymphocytes, antigen presenting cells and tumor cells and induce an immunological anti-tumor response. If on the one hand these molecules have led to considerable improvement in survival outcomes, on the other hand these therapies can be associated with immune-related adverse effects (irAEs). While these side effects have become well known, the best diagnostic and therapeutic approaches are still under investigation. The authors discuss pathophysiology, clinical presentation and histological features of ICIs renal toxicity. Furthermore, we focus on kidney transplant (KT) recipients, including the therapeutic adaptation approach to immunosuppression and the risk of rejection.

Interest & Impact

Downloads

4 since deposited on 10 Jun 2024
4 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item